Non-invasive biomarkers and scoring systems show strong capability in differentiating chronic liver disease from cirrhosis, ...

Women who experience menopause before the age of 50—and especially before the age of 45—are more likely to develop fatty ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Fatty liver disease, also known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a chronic liver ...

To test their new drug, the researchers conducted experiments on mice that were fed a high-fat diet, which typically leads to ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) have an increased risk of giving birth prematurely and the risk increase cannot be explained by obesity, according ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

An experimental new treatment is showing early promise in the fight against liver fibrosis – a serious and often silent ...

Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Metabolic liver disease might not get as much attention as heart disease or diabetes, but it affects around one in four ...